News

New cancer target draws €259m
Enlarge image

BusinessUK

New cancer target draws €259m

11.12.2012 - British pharma GlaxoSmithKline fosters its transatlantic ties. Texas-based MD Anderson will receive €259m for a cancer immune therapy programme.

GlaxoSmithKline (GSK) secured a promising cancer immune therapy programme by collaborating with University of Texas MD Anderson from Houston (US). The deal, which allots GSK worldwide exclusive rights, was been made public on 7 December. In total, the pharma company could pay more than €259m in upfront and milestone payments, excluding the royalties of possible therapeutic antibody sales.

The programme in question has been established by former MD Anderson professor Yong-Jun Liu who is now working at the Baylor Research Institute in Dallas. Liu found that an activation of the T cell receptor OX40 (CD134) on the surface of dendritic cells improves the chances of an immune attack mediated by these cells: "T cell recognition of a tumour antigen is not enough to activate the T cells against cancer cells, they need a secondary signal to tell them “that antigen you have is a bad thing, you have to attack,'“ Liu said. Hence, he and his team screened for antibodies that could mimic the natural activator OX40L, which enables amplification of Th2 cell differentiation upon binding to its receptor. Right now the candidates have been boiled down to half a dozen. The collaboration with GSK in this late preclinical stage comes as no surprise for Liu: "It is gratifying to see this important step towards translating a basic science discovery into a potential new therapy that can proceed to clinical trial.“

The agreement between academia and economy is the first pact for MD Anderson’s new Institute for Applied Cancer Science (IACS). This institute is one of several projects of the recently launched ‚Moon Shot Program’ that tries to advance discoveries from basic sciences into the clinic. Dubbed as the „nation’s No. 1 hospital for cancer care“, MD Anderson thinks that „the end of cancer is closer than you think.“ Other cancer types included in the Moon Shots Program are breast and ovarian cancers, leukaemia (AML/MDS as well as CLL), lung cancer, melanoma and prostate cancer.

It is not the first time that a company aims to target OX40. The human MAB oxelumab targets not the receptor but its ligand OX40L. After Phase II trails in allergic asthma patients failed, Roche's US subsidiary Genentech terminated the development of oxelumab (huMAb OX40L) with Danish Genmab in Q2/2011.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/new-cancer-drug-target-draws-eur259m.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014